Ke S - Search Results

1

Activity of pp60c-src in 60 different cell lines derived from human tumors.

Budde RJ, Ke S, Levin VA. Budde RJ, et al. Among authors: ke s. Cancer Biochem Biophys. 1994 Oct;14(3):171-5. Cancer Biochem Biophys. 1994. PMID: 7537173

2

Recombinant pp60c-src from baculovirus-infected insect cells: purification and characterization.

Budde RJ, Ramdas L, Ke S. Budde RJ, et al. Among authors: ke s. Prep Biochem. 1993 Nov;23(4):493-515. doi: 10.1080/10826069308544572. Prep Biochem. 1993. PMID: 7504254

3

Use of synthetic peptides and copolymers to study the substrate specificity and inhibition of the protein tyrosine kinase pp60c-src.

Budde RJ, Obeyesekere NU, Ke S, McMurray JS. Budde RJ, et al. Among authors: ke s. Biochim Biophys Acta. 1995 Apr 5;1248(1):50-6. doi: 10.1016/0167-4838(94)00232-6. Biochim Biophys Acta. 1995. PMID: 7536039

4

The C-terminal Src kinase (Csk) is widely expressed, active in HT-29 cells that contain activated Src, and its expression is downregulated in butyrate-treated SW620 cells.

Li S, Ke S, Budde RJ. Li S, et al. Among authors: ke s. Cell Biol Int. 1996 Nov;20(11):723-9. Cell Biol Int. 1996. PMID: 8979366

5

Csk phosphorylation and inactivation in vitro by the cAMP-dependent protein kinase.

Sun G, Ke S, Budde RJ. Sun G, et al. Among authors: ke s. Arch Biochem Biophys. 1997 Jul 15;343(2):194-200. doi: 10.1006/abbi.1997.0156. Arch Biochem Biophys. 1997. PMID: 9224730

6

Cyclic peptides as probes of the substrate binding site of the cytosolic tyrosine kinase, pp60c-src.

McMurray JS, Budde RJ, Ke S, Obeyesekere NU, Wang W, Ramdas L, Lewis CA. McMurray JS, et al. Among authors: ke s. Arch Biochem Biophys. 1998 Jul 1;355(1):124-30. doi: 10.1006/abbi.1998.0707. Arch Biochem Biophys. 1998. PMID: 9647675

7

Cyclic peptides incorporating 4-carboxyphenylalanine and phosphotyrosine are potent inhibitors of pp60(c-)(src).

Wang W, Ramdas L, Sun G, Ke S, Obeyesekere NU, Budde RJ, McMurray JS. Wang W, et al. Among authors: ke s. Biochemistry. 2000 May 2;39(17):5221-8. doi: 10.1021/bi992994f. Biochemistry. 2000. PMID: 10819990

We have been employing cyclic decapeptides to identify the determinants for substrate binding and phosphorylation to develop inhibitors competitive with protein substrates of Src. A structure-activity study [McMurray, J. S., Budde, R. J. A., Ke, S., Obeyeseke …

We have been employing cyclic decapeptides to identify the determinants for substrate binding and phosphorylation to develop inhibitors comp …

8

Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.

Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn A, Herbst RS, Li C, Lee HY. Oh SH, et al. Among authors: ke s. Mol Cancer Ther. 2006 Nov;5(11):2685-95. doi: 10.1158/1535-7163.MCT-06-0142. Mol Cancer Ther. 2006. PMID: 17121915

9

Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.

Li C, Price JE, Milas L, Hunter NR, Ke S, Yu DF, Charnsangavej C, Wallace S. Li C, et al. Among authors: ke s. Clin Cancer Res. 1999 Apr;5(4):891-7. Clin Cancer Res. 1999. PMID: 10213226

10

Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts.

Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, Li C. Ke S, et al. Cancer Res. 2003 Nov 15;63(22):7870-5. Cancer Res. 2003. PMID: 14633715

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,038 results

Search Page